PharmaCyte BiotechPMCB -3.90%32 Return-on-Tangible-Equity is 8.20% as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,200 Biotechnology companies, PharmaCyte Biotech ranks better than 71.25% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PharmaCyte Biotech's annualized net income for the quarter that ended in Jan. 2026 was $2.99 Mil. PharmaCyte Biotech's average shareholder tangible equity for the quarter that ended in Jan. 2026 was $36.43 Mil. Therefore, PharmaCyte Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2026 was 8.20%.
The historical rank and industry rank for PharmaCyte Biotech's Return-on-Tangible-Equity or its related term are showing as below:
PMCB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -252.52 Med: -135.2 Max: 69.43
Current: -8.04
During the past 13 years, PharmaCyte Biotech's highest Return-on-Tangible-Equity was 69.43%. The lowest was -252.52%. And the median was -135.20%.
PMCB's Return-on-Tangible-Equity is ranked better than 71.25% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs PMCB: -8.04
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
PharmaCyte Biotech Return-on-Tangible-Equity Related Terms
PharmaCyte Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMCB vs ERNA, SYBX, ASBP: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, PharmaCyte Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jan. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.20% mean?
PharmaCyte Biotech (PMCB) has a Return-on-Tangible-Equity of 8.20% as of Jan. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #345 out of 1200 companies in the Biotechnology industry, placing it in the top 28.7%.
Is PharmaCyte Biotech's Return-on-Tangible-Equity too high?
PharmaCyte Biotech's current Return-on-Tangible-Equity is 8.20%. Based on the distribution chart, PharmaCyte Biotech ranks #345 out of 1200 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Return-on-Tangible-Equity compare to ERNA and SYBX?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #345 out of 1200 companies for Return-on-Tangible-Equity. This puts PharmaCyte Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Return-on-Tangible-Equity is 8.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Return-on-Tangible-Equity of 8.20%. The current Return-on-Tangible-Equity is 8.20%. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Return-on-Tangible-Equity is 8.20% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
